Affimed (AFMD) Competitors $0.93 +0.04 (+5.02%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.97 +0.03 (+3.67%) As of 04/25/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AFMD vs. PRLD, CTOR, CYCC, VRCA, XLO, CNTB, MRSN, SKYE, SPRO, and TNYAShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Prelude Therapeutics (PRLD), Citius Oncology (CTOR), Cyclacel Pharmaceuticals (CYCC), Verrica Pharmaceuticals (VRCA), Xilio Therapeutics (XLO), Connect Biopharma (CNTB), Mersana Therapeutics (MRSN), Skye Bioscience (SKYE), Spero Therapeutics (SPRO), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. Affimed vs. Prelude Therapeutics Citius Oncology Cyclacel Pharmaceuticals Verrica Pharmaceuticals Xilio Therapeutics Connect Biopharma Mersana Therapeutics Skye Bioscience Spero Therapeutics Tenaya Therapeutics Affimed (NASDAQ:AFMD) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership. Is AFMD or PRLD more profitable? Prelude Therapeutics has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Prelude Therapeutics' return on equity of -66.89% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Affimed-7,836.26% -193.84% -107.24% Prelude Therapeutics N/A -66.89%-55.59% Do insiders and institutionals have more ownership in AFMD or PRLD? 30.8% of Affimed shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 62.8% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor AFMD or PRLD? Affimed received 408 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 69.79% of users gave Affimed an outperform vote while only 50.00% of users gave Prelude Therapeutics an outperform vote. CompanyUnderperformOutperformAffimedOutperform Votes43969.79% Underperform Votes19030.21% Prelude TherapeuticsOutperform Votes3150.00% Underperform Votes3150.00% Which has preferable earnings and valuation, AFMD or PRLD? Affimed has higher earnings, but lower revenue than Prelude Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAffimed$877K17.16-$114.66MN/AN/APrelude Therapeutics$7M7.27-$121.83M-$1.69-0.53 Which has more risk & volatility, AFMD or PRLD? Affimed has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Does the media prefer AFMD or PRLD? In the previous week, Affimed had 12 more articles in the media than Prelude Therapeutics. MarketBeat recorded 14 mentions for Affimed and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.93 beat Affimed's score of 0.50 indicating that Prelude Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Affimed 1 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AFMD or PRLD? Affimed presently has a consensus price target of $13.50, suggesting a potential upside of 1,344.31%. Prelude Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 344.00%. Given Affimed's stronger consensus rating and higher probable upside, analysts plainly believe Affimed is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryAffimed beats Prelude Therapeutics on 9 of the 16 factors compared between the two stocks. Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.05M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.31%P/E RatioN/A7.1422.1418.40Price / Sales17.16238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.226.266.664.18Net Income-$114.66M$142.48M$3.21B$247.71M7 Day Performance27.43%7.90%6.21%6.61%1 Month Performance12.82%-4.23%-2.82%-2.21%1 Year Performance-81.42%-2.70%16.44%4.68% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed3.8315 of 5 stars$0.93+5.0%$13.50+1,344.3%-80.8%$15.05M$877,000.000.00200Analyst ForecastPRLDPrelude Therapeutics2.3868 of 5 stars$0.80-1.4%$4.00+400.8%-77.7%$45.09M$7M-0.45120News CoverageGap DownCTORCitius OncologyN/A$0.62-7.6%$3.00+383.1%N/A$44.43MN/A0.00N/APositive NewsGap UpCYCCCyclacel Pharmaceuticals2.8485 of 5 stars$0.21-6.6%$11.00+5,110.8%-82.6%$43.77M$74,000.00-0.0214Dividend AnnouncementAnalyst ForecastNews CoveragePositive NewsGap UpVRCAVerrica Pharmaceuticals3.3634 of 5 stars$0.47-5.1%$9.50+1,941.3%-92.6%$42.71M$7.57M-0.2540Positive NewsXLOXilio Therapeutics2.5798 of 5 stars$0.82+8.4%$4.00+390.8%-18.0%$42.20M$6.34M-0.4770Negative NewsCNTBConnect Biopharma3.1686 of 5 stars$0.75+0.8%$8.00+973.8%-42.1%$41.24M$24.12M0.00110Positive NewsGap UpMRSNMersana Therapeutics3.726 of 5 stars$0.33-7.8%$4.00+1,123.6%-87.2%$40.74M$40.50M-0.54150Gap UpSKYESkye Bioscience1.0127 of 5 stars$1.53-44.1%$16.60+988.5%-85.8%$40.58MN/A-1.9911News CoverageGap UpSPROSpero Therapeutics4.5089 of 5 stars$0.73-3.9%$5.00+589.7%-49.3%$40.53M$27.40M10.36150Positive NewsTNYATenaya Therapeutics3.5048 of 5 stars$0.46+1.8%$6.25+1,264.0%-88.4%$40.13MN/A-0.32110Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies PRLD Competitors CTOR Competitors CYCC Competitors VRCA Competitors XLO Competitors CNTB Competitors MRSN Competitors SKYE Competitors SPRO Competitors TNYA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AFMD) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
